January 15, 2024

SAN RAMON, CALIF., January 15, 2024CooperVision will shine a spotlight on myopia management and specialty lenses at the 2024 Global Specialty Lens Symposium (GSLS) with multiple education sessions and scientific programs to advance the way that eye care practitioners (ECPs) deliver clinical care. The event—which will take place January 17-20 in Las Vegas—will feature several professional educational sessions, as well as a robust scientific program.

“A huge part of our partner-centric leadership is to provide ECPs with relevant education, high-value tools and resources to help them to grow their practices,” said Tony Sommer, General Manager, Myopia Management & Specialty Contact Lenses, CooperVision, Americas. “Our goal is for ECPs to leave GSLS feeling more confident prescribing our innovative portfolio of contact lenses and positively impacting the quality of life of their patients.”

CooperVision will sponsor multiple discussions surrounding myopia management and irregular cornea over three days, including:

  • Myopia Management Made Easy with MiSight® 1 day
    Breakfast Seminar
    Thursday, January 18 | 7:30 – 7:55 a.m. PT
    Justin Kwan, OD, FAAO, CooperVision
  • Elevate Your Empirical Hybrid Fitting Game
    Lunch & Learn
    Thursday, January 18 | 12:55 – 2:00 p.m. PT
    Tiffany Andrzejewski, OD, and Rob Ensley, OD
  • Building Confidence and Improving First Fit Success with Paragon CRT®
    Thursday, January 18 | 2:10 – 2:55 p.m. PT
    Maria Liu, OD, FAAO, PhD, UC Berkeley School of Optometry, and Leah Johnson, OD, FAAO, FSLS, CooperVision
  • Tooling Around…The Latest Innovations in Scleral Lens Fitting Tools
    Friday, January 19 | 1:30 – 2:15 p.m. PT
    Renee Reeder, OD, FAAO, FSLS and Shalu Pal, OD, FAAO, FSLS
  • 5X Revenue Per Patient with Myopia Management
    Friday, January 19 | 5:30 – 6:15 p.m. PT
    Justin Kwan, OD, FAAO, CooperVision
  • Reinventing the Specialty Customer Experience
    Breakfast Seminar
    Saturday, January 20 | 7:30 – 7:55 a.m. PT
    Tony Sommer, MBA, CooperVision and Marie-Christine Blanchard, CooperVision

In addition, the company will share several scientific papers and posters at GSLS, reinforcing its commitment to taking an evidence-based approach to care. Among those are a new exploration of trends in U.S. pediatric eye exams and contact lens prescribing, an in-depth analysis of MiSight® 1 day efficacy for children who exhibit slower and faster myopia progression. More details are expected to be released in the coming days.

Now prescribed in more than 30 countries, CooperVision’s MiSight® 1 day is the first and only soft contact lens approved by the FDA* to both correct vision and slow the progression of myopia in children aged 8-12 at the initiation of treatment.†1

For additional information about CooperVision and its contact lens portfolio, please visit www.coopervision.com.


U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

Compared to a single vision 1-day lens over a 3-year period.


1. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.

About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com

About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women’s health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com

Media Contact
Maggie O’Donoghue, Counselor
McDougall Communications for CooperVision
maggie@mcdougallpr.com or +1-(585)-208-8534